🇺🇸 FDA
Pipeline program

pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

IIT20240161C-R1

Phase 2 small_molecule active

Quick answer

pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy for HER2-positive Breast Cancer is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
HER2-positive Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials